Loading company…
San Diego biotech developing gene engineering technologies and allogeneic CAR-T therapies for cancer and genetic disorders.
Founded in 2014 and based in San Diego, US, Poseida Therapeutics, Inc. develops gene engineering technologies, including the piggyBac DNA Delivery System and Cas-CLOVER gene editing. It generated revenue of USD 130,492,000 in 2022 from partnerships and licensing, earning milestone payments and royalties. The company raised USD 224 mn in its July 9, 2020 IPO on Nasdaq, and Eric Ostertag is CEO. Stage is recorded as Series D.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in